Hasil Pencarian (1)
small molecule | CAS: 849217-68-1
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer.[L15123] In 2016, a capsule…
Kategori:
AmidesAminesAniline Compounds
+16
Target Protein:
Hepatocyte growth factor receptorVascular endothelial growth factor receptor 2Proto-oncogene tyrosine-protein kinase receptor Ret
Waktu ParuhCabozantinib has a …
Vol. DistribusiThe volume of distr…
KlirensAt steady state, th…
Genetik
-